Yuji Ikeda

Yuji Ikeda

Auto-generated profile, based on publicly available information

Yuji Ikeda

Department of Obstetrics and Gynecology, Nihon University School of Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
TMTatsuo Matsuda
Tatsuo Matsuda
MLMatthias Leisegang
Matthias Leisegang
JPJae-Hyun Park
Jae-Hyun Park
LRLili Ren
Lili Ren
TKTaigo Kato
Taigo Kato
YNYusuke Nakamura
Yusuke Nakamura
Purpose: Current evolution of cancer immunotherapies, such as immune checkpoint blockade, has implicated neoantigens as major targets of anticancer cytotoxic T cells. Adoptive T-cell therapy with neoantigen-specific T-cell receptor (TCR)–engineered T cells would be an attractive therapeutic option for advanced cancers where the host antitumor immune function is strongly inhibited. We previously developed a rapid and efficient pipeline for production of neoantigen-specific TCR-engineered T cells using peripheral blood from an HLA-matched healthy donor. Our protocol required only 2 weeks from stimulation of T cells with neoantigen-loaded dendritic cells to the identification of neoantigen-specific TCRs. We conducted the pilot study to validate our protocol. Experimental Design: We used tumors from 7 ovarian cancer patients to validate our protocol. Results: We chose 14 candidate neoantigens from 7 ovarian tumors (1–3 candidates for each patient) and then successfully induced three neoantigen-specific T cells from 1 healthy donor and identified their TCR sequences. Moreover, we validated functional activity of the three identified TCRs by generating TCR-engineered T cells that recognized the corresponding neoantigens and showed cytotoxic activity in an antigen dose–dependent manner. However, one case of neoantigen-specific TCR-engineered T cells showed cross-reactivity against the corresponding wild-type peptide. Conclusions: This pilot study demonstrated the feasibility of our efficient process from identification of neoantigen to production of the neoantigen-targeting cytotoxic TCR-engineered T cells for ovarian cancer and revealed the importance of careful validation of neoantigen-specific TCR-engineered T cells to avoid severe immune-related adverse events. Clin Cancer Res; 24(21); 5357–67. ©2018 AACR. See related commentary by Anczurowski and Hirano, p. 5195

1 April 2017 in Gynecologic Oncology
Verified
Journal Article
Closed access
KMKoji Matsuo
Koji Matsuo
KOKohei Omatsu
Kohei Omatsu
MRMalcolm S. Ross
Malcolm S. Ross
MJMarian S. Johnson
Marian S. Johnson
MYMayu Yunokawa
Mayu Yunokawa
LRLynda D. Roman
Lynda D. Roman

14 August 2017 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
VSVassiliki Saloura
Vassiliki Saloura
AFAiman Fatima
Aiman Fatima
MZMakda Zewde
Makda Zewde
KKKazuma Kiyotani
Kazuma Kiyotani
RBRyan Brisson
Ryan Brisson
YNYusuke Nakamura
Yusuke Nakamura
Purpose: Squamous cell carcinoma of the head and neck (SCCHN) is a lethal cancer with a suboptimal 5-year overall survival of approximately 50% with surgery and/or definitive chemoradiotherapy. Novel treatments are thus urgently awaited. Immunotherapy with checkpoint blockade has emerged as a promising option for patients with recurrent/metastatic SCCHN; however, it has not been investigated in the curative-intent setting yet. The purpose of this study was to investigate the T-cell receptor repertoire and the tumor microenvironment in tumor tissues of SCCHN patients with locoregionally advanced disease. Experimental Design: We performed T-cell receptor sequencing of tumor tissues from 44 patients with locoregionally advanced SCCHN prior to treatment with definitive chemoradiotherapy and correlated the T-cell clonality and the mRNA expression levels of immune-related genes with clinicopathologic parameters. Results: Clonal expansion of T cells was significantly higher in human papilloma virus (HPV)–negative compared with HPV-positive tumors, signifying more robust antigen presentation in HPV-negative tumors. The latter was supported by the higher percentage of HPV-negative tumors expressing HLA-A protein compared with HPV-positive tumors (P = 0.049). Higher GRZB levels correlated significantly with longer recurrence-free survival (log-rank, P = 0.003) independent of tumor size, nodal stage, and HPV status. Conclusions: Our findings support clonal expansion of T cells in SCCHN patients with locoregionally advanced disease and imply differences in the antigen presentation capacity between HPV-negative and HPV-positive tumors. Elevated GRZB mRNA levels may also serve as a favorable and independent predictor of outcome in SCCHN patients treated with chemoradiotherapy. These data provide rationale for the introduction of immunotherapeutic approaches in the curative-intent setting. Clin Cancer Res; 23(16); 4897–907. ©2017 AACR.

1 April 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
YIYuji Ikeda
Yuji Ikeda
KAKatsuyuki Adachi
Katsuyuki Adachi
KTKensuke Tomio
Kensuke Tomio
SESatoko Eguchi-Kojima
Satoko Eguchi-Kojima
TTTetsushi Tsuruga
Tetsushi Tsuruga
KKKei Kawana
Kei Kawana
Cervical intraepithelial neoplasia (CIN), a precursor lesion to cervical cancer, is caused by high-risk human papillomavirus (HPV); high-grade CIN lesions (CIN2-3) are precancerous and require treatment. No globally approved therapy is available for CIN2-3 treatment. This study is a placebo-controlled randomized clinical trial of GLBL101c treatment for CIN2 in 40 patients with HPV16-positive CIN2 who were 1:1 randomized to receive GLBL101c (1 g/daily) or placebo for 5 days at 1, 2, 4, and 8 weeks. No differences were noted between the GLBL101c and placebo groups for patient background and adverse events. Moreover, no statistically significant difference was noted between the two groups at the primary endpoint, pathological regression after 16 weeks of the first oral dose; however, only in the GLBL101c group, two patients had complete regression (CR; regression to normal within 16 weeks). IFNγ production was significantly correlated with the number of spots identified by the interferon gamma enzyme-linked immunospot (IFNγ-ELISPOT) assay using cervical lymphocytes (CxLs) or peripheral blood mononuclear cells. In the two cases of CR, E7-specific Th1 immune responses were observed at week 16. Therefore, we concluded as a novel Lactobacillus-based vaccine with stronger immunogenicity than GLBL101c should be developed.

1 February 2017 in Gynecologic Oncology
Verified
Journal Article
Closed access
KMKoji Matsuo
Koji Matsuo
MRMalcolm S. Ross
Malcolm S. Ross
SBStephen H. Bush
Stephen H. Bush
MYMayu Yunokawa
Mayu Yunokawa
EBErin A. Blake
Erin A. Blake
LRLynda D. Roman
Lynda D. Roman

1 January 2016 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
YIYuji Ikeda
Yuji Ikeda
AFAkiko Furusawa
Akiko Furusawa
RKRyo Kitagawa
Ryo Kitagawa
ATAya Tokinaga
Aya Tokinaga
FIFuminori Ito
Fuminori Ito
NYNobuo Yaegashi
Nobuo Yaegashi
Ikeda Y, et al. J Gynecol Oncol. 2015 Dec;27(3):e29. http://dx.doi.org/10.3802/jgo.2016.27.e29